Eosinophilia is an established marker of asthma-related inflammation. We assessed the effect of omalizumab on peripheral blood eosinophil counts using a pooled analysis of data from five randomized, double-blind, placebo-controlled studies in patients with moderate-to-severe persistent allergic asthma receiving moderate-to-high-dose inhaled corticosteroids (omalizumab, n Z 1136; placebo, n Z 1100). Relationships between omalizumab, peripheral blood eosinophils, serum free IgE concentrations and clinical outcomes were explored. Baseline mean eosinophil counts were similar in each treatment group. Post-treatment eosinophil counts were significantly reduced from baseline in the omalizumab group (p < 0.0001) but were not significantly different in the placebo group. Greater reductions in eosinophil counts were observed in patients who had post-treatment free IgE levels <50 ng/mL. Three studies included steroid-stable and steroidreduction phases. At the end of each phase in these studies, a significantly greater reduction in eosinophil counts was achieved in the omalizumab group compared with the placebo group (p < 0.0001). A consistent pattern of improved clinical outcomes/decreased eosinophils and worsened clinical outcomes/increased eosinophils was observed for both omalizumab and placebo treatment groups. The findings from our analysis of a large patient population are consistent with earlier reports of the inhibitory effect of omalizumab on eosinophils. ª
Introduction
Asthma is a chronic inflammatory disorder of the airways that is often allergic in nature and characterized by the presence of immunoglobulin E (IgE) antibodies against one or more common environmental allergens. 1e5 The main phases of allergic asthma are: sensitization to an allergen, an early asthmatic response (within minutes of allergen exposure), a late asthmatic response (within hours/days of allergen exposure), and airway remodelling. The important role of eosinophils in inflammation is well documented, and eosinophilia is established as a good marker of inflammation in patients with asthma. 3, 6 Eosinophils release a variety of pro-inflammatory mediators including granule-stored cationic proteins, newly synthesized eicosanoids and cytokines. 3, 6 Furthermore, sputum eosinophil counts correlate closely with asthma severity 7 and both the risk and severity of exacerbations. 8, 9 Anti-IgE therapy with omalizumab, added to medium-or high-dose inhaled corticosteroids (ICS), with or without a long-acting b 2 -agonist, has proven effective in the treatment of patients with moderate-to-severe and severe allergic (IgE-mediated) asthma by reducing exacerbations and associated use of rescue bursts of systemic corticosteroids in addition to improving other clinical outcomes. 10e16 Omalizumab results in a rapid reduction in free IgE levels and correspondingly downregulates Fc3RI expression on basophils and mast cells. These actions reduce IgE-mediated responses to allergens, mast cell degranulation and release of pro-inflammatory mediators. 4,17e20 Omalizumab has also been shown to reduce Fc3RI expression on antigen-presenting cells (dendritic cells [DCs] ) prior to their trafficking into tissues, 21 suggesting that omalizumab may have the unique capacity to block both sensitization and effector phases of the allergic inflammatory process. There is evidence that blocking IgE with omalizumab leads to an inhibitory effect on eosinophils. Djukanović et al. 17 reported that omalizumab monotherapy significantly reduced the number of sputum and bronchial submucosal eosinophils in patients with allergic asthma not receiving ICSs. This observed decrease in sputum and bronchial submucosal eosinophils was accompanied by a reduction in submucosal IgEþ and Fc3RIþ cells.
The aim of this analysis was to assess the effect of omalizumab on peripheral blood eosinophil counts in patients with moderate-to-severe persistent allergic asthma. In addition, the relationships between peripheral blood eosinophils, serum free IgE concentrations and clinical outcomes were explored.
Methods

Studies and patients
This pooled analysis included data from five randomized, double-blind, placebo-controlled pivotal registration trials that assessed efficacy and safety of omalizumab in the treatment of patients with moderate-to-severe persistent allergic asthma (Table 1) . 10e14 In all studies, patients were !12 years of age and were receiving ongoing therapy with at least moderate-to-high doses of ICS at baseline. A monthly dose of omalizumab of at least 0.016 mg/kg/IU IgE was administered subcutaneously every 2 or 4 weeks, according to a dosing table nomogram incorporating the patient's bodyweight and baseline IgE levels.
The treatment period in three studies consisted of two phases: (1) a 16-week 'steroid-stable' phase during which patients received omalizumab or placebo treatment in addition to a fixed dose of ICS; and (2) 12e14 in the placebo group (p < 0.01). Two studies 12, 13 were also followed by extension phases that were similar in design. 22, 23 Briefly, during the 24-week double-blind extension phase, patients were maintained on omalizumab or placebo and the lowest sustainable dose of beclomethasone dipropionate (BDP). The use of other asthma medications was permitted and investigators were allowed to switch patients from BDP to other ICS medications. Full details of the five study designs have been reported elsewhere.
10e14
Circulating eosinophil counts and serum free IgE concentrations Blood samples were obtained at baseline and post-treatment for measurement of the complete blood count (CBC) including eosinophils. The CBC was analyzed using the Bayer Advia 120 automated hematology system. Eosinophil counts greater than 15% were confirmed by manual differential. The post-treatment (omalizumab or placebo) time point was taken as the first available eosinophil laboratory evaluation after (and including) Week 16. In the three steroid-reduction studies, 12e14 eosinophil counts were also calculated at the end of the 'steroid-reduction' phase. In the two studies with extension phases, 22, 23 change in eosinophil counts were calculated at the end of the extension phase, taken as the eosinophil laboratory evaluation at Week 52.
Blood samples were also collected for measurement of serum total and free IgE at baseline and post-treatment. Baseline pretreatment total IgE concentrations in serum was determined by a microparticle enzyme immunoassay test kit commercially available from Abbott Inc. Free IgE was measured using a solid-phase ELISA, as described previously. 24 Eosinophil counts in subgroups of serum free IgE levels <50 ng/mL and ‡50 ng/mL For the studies from which IgE data were available, 10,12e14 changes from baseline to post-treatment in mean eosinophil counts were grouped according to patients who achieved suppression of free IgE levels to <50 ng/mL d vs patients who had not (i.e. free IgE levels !50 ng/mL).
Eosinophil counts in subgroup of patients receiving maintenance oral corticosteroids (OCS) at baseline
Changes from baseline to post-treatment in mean eosinophil counts were determined for those patients receiving maintenance OCS at baseline.
Clinical outcomes
The clinical outcomes assessed were: (1) total number of steroid bursts associated with treatment of asthma exacerbations 10, 11 ; (2) investigator's global evaluation of treatment effectiveness (GETE) which was rated as 'excellent/good', 'moderate', or 'poor/worse'; and (3) lung function assessed as change from baseline in forced expiratory volume in 1 s (FEV 1 ). The effect of omalizumab on steroid bursts and GETE was determined at the end of the 'steroid-reduction' phase 12e14 or the end of the study. 10, 11 A steroid burst was defined as a dose of oral prednisone (40e60 mg) in single or two divided daily doses for adults or 1e2 mg/kg/day (maximum 60 mg/day) for patients less than 18 years, generally administered for 3e10 days. The last non-missing observation in the 'steroidstable' phase was considered the end of study FEV 1 measurement for the three studies that had a 'steroidreduction' phase. 12e14 The last non-missing observation after the treatment phase was considered the end of study FEV 1 measurement for the remaining two studies. 10, 11 The relationships between changes in eosinophil counts and clinical outcomes were explored.
Statistical methods
Absolute eosinophil counts at baseline and post-baseline time points were summarized descriptively for the omalizumab and placebo group and the mean change from baseline calculated. T-tests were used to determine if mean changes were different from zero for each treatment group. The two-tailed null hypothesis stated that the mean change from baseline to the post-baseline time point in eosinophil counts was not different from zero. For each post-baseline time point, change from baseline was analyzed using an analysis of covariance (ANCOVA) model with baseline eosinophil value, age, gender, treatment group (omalizumab or placebo), dosing schedule (every 2 or 4 weeks) and study centre as explanatory variables. Least squares means (LSM) were computed for each treatment group as well as 95% confidence intervals (CIs) for LSM treatment differences and p-values for the treatment difference. The number of asthma exacerbations requiring steroid bursts was analyzed using Poisson regression with treatment, age, gender, use of oral steroids at baseline, baseline FEV 1 (!80%, 60e79%, <60%), dosing schedule and study as explanatory variables. 25, 26 The relative risk (RR) for omalizumab versus placebo was calculated and presented with corresponding 95% CI. Investigator-determined GETE were analyzed using CochraneManteleHaenszel mean score test adjusting for study. 25 Change from baseline in FEV 1 was analyzed using ANCOVA with treatment, age, gender, baseline FEV 1 , dosing schedule and study as explanatory variables; LSM of the change from baseline and 95% CI were calculated. All analyses were performed using SAS Version 9.1 (Copyright ª 2002e2003 by SAS Institute Inc., Cary, NC, USA). 
Results
Baseline demographic and clinical characteristics
Data for 1136 omalizumab-treated patients and 1100 placebo recipients were analyzed. In the three studies that included a steroid-reduction phase, data were available for 1412 patients (omalizumab: n Z 718; placebo: n Z 694). In the two studies with an extension phase, data were available for 1071 patients (omalizumab: n Z 542; placebo: n Z 529). The treatment groups were well matched in terms of baseline demographic and clinical characteristics (Table 2) . Overall, approximately 96% of patients met GINA 2002 criteria for severe persistent asthma based on both symptoms and asthma therapy. 1 
Eosinophil counts and free IgE levels
Mean eosinophil counts at baseline were similar in the two treatment groups (Table 3) . Post-treatment eosinophil counts were significantly reduced from baseline in the omalizumab group (p < 0.0001) but were not significantly different in the placebo group. The LSM treatment difference for the post-treatment change from baseline in eosinophil counts was À0.051 Â 10 9 /L in favour of omalizumab (p < 0.0001) (Fig. 1) .
In the three studies that comprised 'steroid-stable' and 'steroid-reduction' phases, 12e14 eosinophil counts were significantly reduced from baseline in the omalizumab group at the end of each phase (Table 4 ). There was no significant change in the placebo group at either time point (Table 4) . The LSM treatment difference for the change from baseline in eosinophil counts was À0.057 Â 10 9 /L in favour of omalizumab (p < 0.0001) at the end of the 'steroidstable' phase ( Fig. 2a) and À0.057 Â 10 9 /L in favour of omalizumab (p < 0.0001) at the end of the 'steroid-reduction' phase (Fig. 2b) .
In the two studies with extension phases, 22,23 eosinophil counts were significantly reduced from baseline in the omalizumab group at the end of the extension phase (Table 5) . Changes from baseline in the placebo group were not significant ( Table 5 ). The LSM treatment difference for the change from baseline in eosinophil counts at the end of the extension phase was À0.048 Â 10 9 /L in favour of omalizumab (p < 0.001; Fig. 2c ).
Eosinophil counts in subgroups of serum free IgE levels <50 ng/mL and ‡50 ng/mL
Patients with post-treatment free IgE levels <50 ng/mL (n Z 786) achieved a mean (SD) change in eosinophil counts 
Eosinophil counts in patients receiving maintenance OCS at baseline
Omalizumab patients who were also receiving maintenance OCS at baseline (n Z 88) achieved a mean (SD) decrease in eosinophil count ( 
Clinical outcomes
The mean number of asthma exacerbations requiring treatment with steroid bursts was lower in the omalizumab group compared with placebo ( Table 6 ). The mean (SD) number of steroid bursts was 0.4 (0.87) and 0. Table 6 ). Investigator-determined GETE showed significant improvements in favour of omalizumab. Physicians rated treatment effectiveness as 'excellent' or 'good' in 59% of omalizumab-treated patients compared with 37% in the placebo group (p < 0.001; Table 6 ).
In general, a greater percentage of patients receiving omalizumab experienced an improvement in clinical outcomes and a decrease in eosinophil counts (Table 7) .
Discussion
Findings from this pooled analysis demonstrate that reduction of serum free IgE by omalizumab is associated with a significant reduction in peripheral eosinophil counts in patients with moderate-to-severe persistent allergic asthma receiving moderate-to-high doses of ICS. In the pooled analysis of 5 studies, circulating eosinophils were reduced by a median of 18.8% and 2.1% in the omalizumab and placebo groups, respectively (Table 3 ). In the three studies that included a 'steroid-reduction' phase, reductions in eosinophil counts were maintained despite a significant reduction in ICS dose to levels that are less likely to be associated with systemic activity e circulating eosinophils were reduced in the omalizumab group by a median of 21.2% at the end of the 'steroid-stable' phase and a median of 14.6% at the end of the 'steroid-reduction' phase (at the same time points, eosinophil counts in the placebo group were decreased by a median of 3.7% and increased by 3.6%, respectively; Tables 4 and 5 ).
In two studies, patients entered a long-term extension following the 'steroid-reduction' phase. During the extension phase, omalizumab sustained the decrease in eosinophil counts observed following steroid reduction. These reductions in eosinophil counts following treatment with omalizumab were accompanied by improvements in a range of clinical outcome measures. The significant reduction in eosinophil counts observed in our pooled analysis adds evidence from a large patient population to that obtained from smaller studies, which reported an inhibitory effect of omalizumab on eosinophils. In one study of 35 patients with moderate-to-severe allergic asthma, omalizumab significantly decreased circulating eosinophils at both 16 and 52 weeks (p < 0.01 vs placebo). 27 Evidence of attenuation of eosinophil infiltration into the lungs was provided by Djukanović and colleagues in a study of 45 patients with corticosteroid-naive, mild-to-moderate persistent allergic asthma who underwent bronchial biopsy and induced-sputum sampling. 17 In the omalizumab group, the percentage of eosinophils present in induced sputum decreased from 4.8% to 0.6% (p Z 0.05 vs placebo) and tissue eosinophils in the bronchial submucosa were significantly reduced from 8.0 to 1.5 cells/mm 2 (p Z 0.03 vs placebo).
In a study of 19 patients with coexisting allergic asthma and rhinitis, omalizumab therapy induced eosinophil apoptosis and reduced the number of lymphocytes producing GM-CSF, an important factor for eosinophil growth and survival. 28 Furthermore, a study of 30 adults with seasonal allergic rhinitis reported that blood eosinophils increased significantly in the placebo group, remained unchanged in the omalizumab group, and that differences between treatment groups were statistically significant. 29 The authors also reported that seasonal increases and inhibitory effects of treatment were mirrored in the changes in eosinophils (staining positively for eosinophil peroxidase) in nasal biopsy specimens. Moreover, the number of nasal tissue eosinophils correlated significantly with serum free IgE levels.
Despite having established a considerable evidence base supporting the effects of omalizumab on circulating and bronchial eosinophils, the mechanism whereby reductions in circulating IgE can ultimately lead to a reduction in eosinophils remains unclear. It is possible that omalizumab may lead to inhibition of the release of pro-inflammatory mediators, cytokines and chemokines from mast cells/ basophils, or inhibition of the allergen-induced differentiation of T-cells to Th2 cells by markedly reducing the expression of Fc3RI on these cells. The mediators of greatest interest are the Th2 cytokines IL-4, IL-5 and IL-13 as these are responsible for promoting recruitment and activation of mast cells and eosinophils and are the primary effector cells of the allergic response. 30 It is known that IL-4, IL-5 and IL-13 levels are increased in the sera of patients with asthma. 31 Moreover, IL-4 and IL-13 play a central role in promoting eosinophil trafficking, as well as driving Th2 cell differentiation, whereas IL-5 is the major cytokine promoting eosinophil differentiation, proliferation and activation. 3 Omalizumab has been shown to significantly reduce IL-4 positive cells in the bronchial submucosa and reduce IL-5 positive cells, although this latter reduction was not statistically significant. 17 A significant reduction in circulating IL-13 and a non-significant reduction in circulating IL-5 have also been reported with omalizumab in patients with moderate-to-severe allergic asthma. 27 Eosinophil apoptosis and reduced numbers of lymphocytes producing GM-CSF have been observed in omalizumab-treated patients with coexisting allergic asthma and rhinitis, which may also contribute to the inhibitory action of omalizumab on eosinophils. 28 A direct effect of omalizumab on eosinophils may be possible via the Fc3RI receptors that have been detected on eosinophils; however, their functional significance has yet to be established. 32, 33 Studies examining blood from atopic subjects have detected only negligible surface expression of functional Fc3RI on eosinophils; however, appreciable intracellular staining for Fc3RI was observed. 33, 34 Of note, cross-linking of the surface-expressed receptors did not lead to any detectable degranulation response. 33, 34 Furthermore, a study that sampled eosinophils from transgenic mice found that IL-10 was secreted after Fc3RI activation, suggesting some contribution to the regulation of the immune response. 35 The anti-eosinophilic effects of ICS are well documented 36e38 but it is noteworthy that the significant reductions seen with add-on omalizumab in this analysis were achieved in study populations that were already receiving ICS. Leukotriene modifiers have also demonstrated anti-eosinophilic effects but these were of a smaller magnitude than that achieved using ICS. 39 Of note, it has been reported that the leukotriene receptor antagonist montelukast failed to reduce sputum eosinophilia in patients with high-dose corticosteroid-dependent asthma. 40 In our analysis, a greater proportion of patients receiving omalizumab experienced improvement in clinical outcomes (reduced requirement for treatment of exacerbations with oral steroid bursts, increased FEV 1 , and positive investigator GETE) and a decrease in peripheral blood eosinophils compared to those receiving placebo. A consistent pattern of improved clinical outcomes/ decreased eosinophils and worsened clinical outcomes/ increased eosinophils was observed for both omalizumab and placebo treatment groups. However, the clinical significance of the decrease in peripheral blood eosinophils, and in particular how this is related to improvements in FEV 1 and GETE, is uncertain. Weak associations, as measured by Pearson and Spearman correlation coefficients, were observed between change (decrease) from baseline in eosinophil counts and various clinical variables (data not shown).
In summary, our findings from this pooled analysis of five large randomized controlled studies in patients with moderate-to-severe or severe persistent allergic asthma expand the understanding of the mechanism of action of omalizumab beyond binding of serum IgE to include effects on the marker of inflammation, peripheral blood eosinophils.
